Brief: Innate Pharma H1 Operating Result Turns To Profit Of EUR 8.5 Mln

Innate Pharma SA

15/09/2022 13:37

Sept 15 (Reuters) - INNATE PHARMA SA  IPH.PA :
    * INNATE PHARMA REPORTS FIRST HALF 2022 FINANCIAL RESULTS
AND
BUSINESS UPDATE
    * CASH POSITION OF EUR 158.2 MILLION AS OF JUNE 30, 2022,
ANTICIPATED CASH RUNWAY INTO H2 2024
    * MONALIZUMAB AND IPH5201 DEVELOPED IN COLLABORATION WITH
ASTRAZENECA ADVANCED INTO PHASE 3 AND 2 CLINICAL TRIALS IN LUNG
CANCER
    * MONALIZUMAB TRIGGERING $55M IN MILESTONE PAYMENTS
    * REVENUE AND OTHER INCOME FROM CONTINUING OPERATIONS
AMOUNTED TO
EUR 45.6M IN FIRST HALF
    * OPERATING EXPENSES FROM CONTINUING OPERATIONS ARE EUR
37.1M IN
FIRST HALF
    * A NET INCOME OF EUR 6.3M FOR FIRST HALF OF 2022
    * A NET FINANCIAL LOSS OF EUR 2.1M IN FIRST HALF OF 2022
    * H1 OPERATING INCOME EUR 8.5 MILLION VERSUS LOSS EUR 19.2
MILLION
YEAR AGO

Source text for Eikon:  ID:nBw5ppVDca 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 587 696 600;))